SEC Form 4 · accession 0001190725-16-000301
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Gergen
Officer — Executive VP, COO
Period of report
Jan 15, 2016
Accepted (ET)
Jan 19, 2016 · 3:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 15, 2016 | M | 5,000 | $8.50 | A | 5,748 | D | |
| Common Stock | Jan 15, 2016 | M | 10,000 | $8.50 | A | 15,748 | D | |
| Common StockF2 | Jan 15, 2016 | S | 10,000 | $25.9211 | D | 5,748 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $8.50 | Jan 15, 2016 | M | 5,000 | A | — | Jul 16, 2020 | Common Stock | 5,000 | 127,000 | D |
| Non Qualified Stock Option (right to buy)F2,F1 | $8.50 | Jan 15, 2016 | M | 10,000 | A | — | Jul 16, 2020 | Common Stock | 10,000 | 117,000 | D |
Explanation of responses
- F120% of the shares subject to the option vested and became exercisable on the Date of Grant, and 20% of tbe shares vest on each of the 1st, 2nd, 3rd and 4th anniversaries of February 15, 2013
- F2The price quoted in Table 1, Column 4 and Table 2, Column 8 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $27.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.